Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrobiosystems CoSZSE:301080 -0.12%92 Days Payable is 269.90 as of Mar. 2026, which is 56% above its 10-year median of 172.95. GuruFocus rates SZSE:301080 with a GF Score™ of 92/100 and a GF Value™ of ¥59.87 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 704 Biotechnology companies, Acrobiosystems Co ranks better than 73.3% on this metric.
The historical rank and industry rank for Acrobiosystems Co's Days Payable or its related term are showing as below:
SZSE:301080'
s Days Payable Range Over the Past 10 Years
Min: 50.42 Med: 172.95 Max: 604.95
Current: 344.49
During the past 9 years, Acrobiosystems Co's highest Days Payable was 604.95. The lowest was 50.42. And the median was 172.95.
SZSE:301080's Days Payable is ranked better than 73.3% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs SZSE:301080: 344.49
Acrobiosystems Co's Days Payable
declined
from Mar. 2025 (412.36) to Mar. 2026 (269.90).
It may suggest that Acrobiosystems Coaccelerated paying its suppliers.
The historical data trend for Acrobiosystems Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301080 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Acrobiosystems Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrobiosystems Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrobiosystems Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Acrobiosystems Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Acrobiosystems Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrobiosystems Co (SZSE:301080) has a Days Payable of 269.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Acrobiosystems Co and its competitors. This is 56% above median its historical median of 172.95. Over the past decade, Acrobiosystems Co's Days Payable has ranged from 50.42 to 604.95. According to the industry distribution chart, Acrobiosystems Co ranks #188 out of 704 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Acrobiosystems Co's Days Payable too high?
Acrobiosystems Co's current Days Payable of 269.90 is 56% above median its 10-year median of 172.95. Over the past 10 years, this metric has ranged from a low of 50.42 to a high of 604.95. The Biotechnology industry median Days Payable is 112.72. Acrobiosystems Co's value of 269.90 is 139.5% above this industry median. Based on the distribution chart, Acrobiosystems Co ranks #188 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Acrobiosystems Co has a GF Score™ of 92/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acrobiosystems Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrobiosystems Co ranks #188 out of 704 companies for Days Payable. This puts Acrobiosystems Co in the upper half of its industry. The industry median Days Payable is 112.72. Acrobiosystems Co's value of 269.90 is 139.5% above this benchmark. Historically, Acrobiosystems Co's own Days Payable has ranged from 50.42 to 604.95 over the past decade. While the company's 10-year median is 172.95 vs. the industry median of 112.72, Acrobiosystems Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrobiosystems Co's current Days Payable of 269.90 is 139.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Acrobiosystems Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrobiosystems Co's current Days Payable is 269.90, which is 56% above median its own 10-year median of 172.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrobiosystems Co stock overvalued right now?
Based on GuruFocus' analysis, Acrobiosystems Co (SZSE:301080) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥59.87, compared to a current price of ¥82.20 — trading 37.3% above its estimated fair value. The current Days Payable is 269.90, which is 56% above median its 10-year median of 172.95 and 139.5% above the Biotechnology industry median of 112.72. Acrobiosystems Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Acrobiosystems Co (SZSE:301080), the current Days Payable is 269.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acrobiosystems Co (SZSE:301080) Overvalued in 2026?
Based on GuruFocus' analysis, Acrobiosystems Co stock appears to be overvalued.
The current stock price of ¥82.20 is trading 37.3% above its estimated GF Value™ of ¥59.87.
GuruFocus considers Acrobiosystems Co to be Significantly Overvalued.
Key valuation signals for SZSE:301080:
Days Payable: 269.90 (56% above median its 10-year median of 172.95)
GF Value™: ¥59.87 vs. price of ¥82.20 (37.3% above fair value)
Industry Position: 139.5% above the Biotechnology median (#188 of 704)
No single metric tells the full story. See the SZSE:301080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
92GF Score
Get the complete analysis for SZSE:301080
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301080 has been successfully added to your 
